Mesoblast (ASX:MSB) share price plunges on FDA decision

The Mesoblast Limited (ASX:MSB) share price could suffer after the FDA's decision about remestemcel-L. 

The Mesoblast Limited (ASX: MSB) share price is down 38% in early trading after the FDA’s decision about remestemcel-L.

What happened?

Mesoblast has been waiting for approval for remestemcel-L from the FDA.

The biotech business announced today that the FDA has issued a ‘complete response letter’ to its application for remestemcel-L for treating pediatric steroid-refractory acute graft versus host disease (SR-aGVHD).

While the Oncologic Drugs Advisory Commitee (ODAC) of the FDA voted 9 to 1 that the available data supported the effectiveness of of remestemcel-L in patients, the FDA has recommended that Mesoblast conduct “at least” one additional randomised, controlled study in adults and/or children to provide further evidence.

Mesoblast said it would urgently request a Type A meeting with the FDA to discuss a potential accelerated approval with a post-approval condition for an additional study considering there are no approved treatments for this condition.

The FDA also identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product’s biological activity. Mesoblast said assays (testing) measuring the potency of remestemcel-L will continue to be refined to provide further scientific rationale for its use in severe inflammatory diseases with high mortality risk.

Mesoblast CEO Dr Silviu Itescu said: “We are working tirelessly to bring remestemcel-L to patients with life threatening inflammatory conditions including SR-aGVHD and COVID-19 ARDS”. 

Summary

This is disappointing news for Mesoblast and delays things for the company. However, it’s not as though the FDA denied remestemcel-L completely. I don’t know enough about the company or the sector, it seems like a binary (yes/no) outcome – which isn’t how I like to invest. With the prior 9 to 1 recommendation, I’d guess it will get through, so this could be an opportunity. But I prefer the idea of other ASX growth shares like Pushpay Holdings Ltd (ASX: PPH) which I wrote about here.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Better investing starts here.

Get Owen’s free Sunday morning newsletter, 
with the best insights in Australia delivered to your inbox.

Skip to content